Ask about this productRelated genes to: CDK6 antibody
- Gene:
- CDK6 NIH gene
- Name:
- cyclin dependent kinase 6
- Previous symbol:
- -
- Synonyms:
- PLSTIRE
- Chromosome:
- 7q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-02-14
- Date modifiied:
- 2019-04-23
Related products to: CDK6 antibody
Related articles to: CDK6 antibody
- Prostate cancer (PCa) is a leading malignancy in men, and understanding its molecular mechanisms is crucial for advancing therapeutic strategies. Ubiquitination, a key post-translational modification, regulates protein degradation and signaling, playing a vital role in cancer progression. This study focuses on HECTD4, a HECT-type E3 ubiquitin ligase, to identify its ubiquitination targets and understand its role in PCa. - Source: PubMed
Takashima YasuoTanaka MasamiYoshii KengoYagi TomohitoMiyagawa-Hayashino AyaTashiro Kei - Egg production is an essential metric used to assess poultry reproductive efficiency. The liver, functioning as a vital metabolic organ, is integral to avian reproduction and the overall productivity of laying birds. In this research, we aimed to explore various aspects of the mechanisms behind egg production across different poultry species by conducting transcriptomic and metabolomic analyses, as well as integrated assessments, of liver tissues from high- and low-producing pigeons to investigate the biosynthesis processes and identify pivotal genes and metabolic pathways in the liver during egg production. There were 1380 differentially expressed genes (DEGs) identified between the low- and high-production groups. The low-production group had 670 upregulated and 710 downregulated genes. Five genes identified were linked to egg production in the transcriptome: PRLR, HMGCR, CDK6, PTGR1 and RBPJ. The pathways that were identified to be the most significant encompass cytokine-cytokine receptor interaction, PI3K-AKT and JAK-STAT signalling pathways. Of the 229 significantly differentially abundant metabolites (DAMs) identified, 71 were upregulated, and 158 were downregulated, of which forskolin, methionine, prostaglandin F2α and adenosine 5'-diphosphate emerged as key metabolites associated with reproduction. By integrating transcriptomic and metabolomic data, we uncovered correlations between specific DEGs and DAMs, revealing significant gene-metabolite pairs, namely, PRLR-prostaglandin F2α and PRLR-adenosine 5'-diphosphate, involved in egg production. The new knowledge substantially enhances our comprehension of the molecular distinctions in hepatic physiology of high- and low-producing pigeons and establishes a valuable theoretical framework for future investigations into the mechanistic basis of avian egg-laying performance. - Source: PubMed
Publication date: 2026/04/21
Chen HuiZhang BinWang ManmanFu YiqianLi JingZhao KailingChen YufeiSong YujieLi YunhaiXu ShanjinDai Dingzhen - - Source: PubMed
Publication date: 2026/04/27
Shuai XueqianSun YaoqiLi JialeGao YuanCheng ZhongpingLiu Shupeng - Cyclin-dependent kinases (CDKs) are key regulators of cell-cycle progression and have long been recognized as attractive therapeutic targets in oncology. Inhibitors of CDK4 and CDK6 have transformed the treatment of patients with breast cancer, providing proof of principle for the clinical utility of CDK inhibition. However, despite extensive research over the past decade, CDK4/6 inhibitors have so far achieved regulatory approval only in this setting. Nonetheless, recent studies refining the optimal use of these drugs have revealed new opportunities to extend their use in other tumour types. Most notably, new combinatorial approaches, particularly with targeted therapies such as HER2 and PI3K inhibitors, are expanding the therapeutic scope of CDK4/6 inhibitors, and insights into resistance mechanisms have driven the development of highly selective CDK2 inhibitors to treat refractory disease. Additionally, efforts to mitigate haematological toxicity have prompted next-generation CDK4-selective inhibitors. Finally, biomarkers, although still underdeveloped clinically, are beginning to inform patient selection. This Review highlights the changes that have occurred in the clinical use of CDK inhibitors since the first FDA approval 10 years ago and the prospects for realizing their broader potential in cancer therapy. - Source: PubMed
Publication date: 2026/04/27
Knudsen Erik SWitkiewicz Agnieszka KKabraji Sheheryar - CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib are commonly used in the clinical treatment of HR-positive, HER2-negative metastatic or locally advanced breast cancer. Patients with metastatic disease often receive palliative radiotherapy for symptom control of bone metastases and/or local lesions, typically administered in close temporal proximity to CDK4/6 inhibitor therapy, although treatment with the inhibitors may be temporarily paused during the radiotherapy period in some cases. In this study, we investigated the extent to which senescence is induced by CDK4/6 inhibitors, ionizing radiation, and the combination of the two, compared to other types of cell fate. Eight breast cancer cell lines with different molecular subtypes and two healthy cell lines (fibroblasts and keratinocytes) were treated with CDK inhibition using palbociclib, ribociclib or abemaciclib and with or without a single dose of 2 Gy ionizing radiation. Cellular senescence, cell death in form of apoptosis and necrosis, and the cell cycle were analyzed using flow cytometry. We focused mainly on understanding how CDK inhibition can trigger cellular senescence. Our data showed that in many cell lines -but not all-the use of CDK inhibitors induced senescence much more strongly than cell death. Except for one cell line, significantly more cell lines died necrotically than apoptotically. Neither apoptosis nor necrosis was responsible for a major cell fate after CDK inhibition. Combination therapy with irradiation did not show a clear additive effect. In cell lines, senescence is clearly triggered by CDK4/6 inhibitors and even more so when in combination with ionizing radiation, which, when transferred to patients, could lead to less damage caused by cell loss, such as necrotic areas. However, it could also lead to more senescence-specific side effects, such as inflammation-induced tumors and fibrosis. - Source: PubMed
Publication date: 2026/04/21
Quarz LisaDistel Luitpold VCorradini StefanieHildebrand Laura S